Background Image
Previous Page  171 / 182 Next Page
Information
Show Menu
Previous Page 171 / 182 Next Page
Page Background

170

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

243

Taylor DR, Webster LR, Chun SY, Reinking J, Stegman M, Shoemaker S, Fortner B. Impact

of breakthrough pain on quality of life in patients with chronic, non-cancer pain: pati-

ent perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTCF,

Actiq). Pain Medicine 2007; 8: 281-288.

244

Twycross R, Wilcock A, Charesworth s, Dickman A. Palliative Care Formulary (2. Aufl.),

Abingdon; Radcliffe Medical Press, 2002.

245

Twycross R, Wilcock A, Thorp S. Palliative care formulary. Abingdon: Radcliffe Medical

Press, 1998.

246

Twycross R. The risks and benefits of corticosteroids in advanced cancer. Drug Safety

1994; 11: 163-178.

247

Überall MA, Müller-Schwefe GHH. Sublingual fentanyl orally disintegrating tablet in dai-

ly practice: efficacy, safety and tolerability in patients with breakthrough cancer pain.

Curr Med Res Opin 2011; 27(7): 1385-1394.

248

Überall MA. Mit fentanylhaltigen Fertigarzneimitteln gegen Durchbruchschmerzen

Schmerztherapie 2009; 2: 6-7.

249

Überall MA. PraxisLeitlinien DGS/DSL: Behandlung tumorbedingter Durchbruchschmer-

zen. Vortrag im Rahmen des Deutschen Schmerztags 2012.

250

Valentín Maganto V, Camps Herrero C, Carulla Torrent J, Cassinello Espinosa J, Dorta

Delgado J, Jara Sánchez C, Moreno Nogueira JA. Safety and efficacy of oral trans-

mucosal fentanyl citrate in the long-term treatment of breakthrough pain in oncology

patients: the ECODIR study. Clin Transl Oncol 2005; 7(5): 205-212.

251

Vasisht N, Gever LN, Tagarro I, Finn AL. Evaluation of the single- and multiple-dose

pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. J Clin

Pharmacol 2010; 50(7): 785-791.

252

Vasisht N, Gever LN, Tagarro I, Finn AL. Single-dose pharmacokinetics of fentanyl buccal

soluble film. Pain Med 2010; 11(7): 1017-1023.

253

Vasisht N, Gever LN, Tagarro I. Formulation selection and pharmacokinetic comparison

of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized,

open- label, single-dose, crossover study. Clin Drug Investig 2009; 29(10): 647-654.

254

Vissers DC, Lenre M, Tolley K, Jakobsson J, Sendersky V, Jansen JP. An economic evalua-

tion of short-acting opioids for treatment of breakthrough pain in patients with cancer.

Value Health 2011; 14(2): 274-281.

255

Wagemans MF, Zuurmond WW, de Lange JJ. Long-term spinal opioid therapy in termi-

nally ill cancer pain patients. Oncologist 1997; 2: 70-75.

256

Walker G, Wilcock A, Manderson C, Weller R, Crosby V. The acceptability of different

routes of administration of analgesia for breakthrough pain. Palliat Med 2003; 17: 219-

221.

257

Weber M, Huber C. Documentation of severe pain, opioid doses, and opioid-related

side effects in outpatients with cancer: a retrospective study. Journal of Pain and Symp-

tom Management 1999; 17: 49-54.

Literaturverzeichnis